Quantel Medical has completed its acquisition of Ellex, including the company’s laser and ultrasound technology solutions (with the exception of 2RT® and iTrack®), via the financial holding company Lumibird Medical.
The coming together of these two companies—both renowned in the field of ophthalmology—represents a real milestone in their history. Quantel Medical and Ellex have a shared heritage in the development of cutting-edge technologies for the diagnosis and treatment of the leading causes of blindness worldwide: glaucoma, cataracts, AMD and diabetic retinopathy.
Since 1985, we've made it our mission to invest in the healing power of ophthalmic laser technology and help to transform the sight and the lives of people across the globe.
Today, more than 35,000 Ellex ophthalmic laser and ultrasound systems are in use in over 100 countries around the world, achieving ophthalmic outcomes once never thought possible — safely, effectively, accurately and consistently.
Every day, Ellex collaborates with leading physicians, teaching institutions and universities to discover, develop and deliver new technologies for the safe and effective treatment of a broad range of eye conditions.
Groundbreaking LiGHT Trial1
“Selective laser trabeculoplasty should be offered as first-line treatment for open angle glaucoma and ocular hypertension, supporting a change in clinical practice.”
Break free from non-compliance and see the light with superior efficacy and safety with SLT from Ellex®, the global market leader.
1LiGHT study, The Lancet. 393.10175